MiNK Therapeutics (NASDAQ:INKT – Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.12), Zacks reports.
MiNK Therapeutics Trading Down 3.9 %
Shares of MiNK Therapeutics stock opened at $7.92 on Thursday. MiNK Therapeutics has a 1-year low of $4.56 and a 1-year high of $19.00. The firm has a fifty day simple moving average of $8.91 and a 200-day simple moving average of $7.75. The stock has a market capitalization of $31.39 million, a price-to-earnings ratio of -2.03 and a beta of 0.16.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of MiNK Therapeutics in a research report on Tuesday.
MiNK Therapeutics Company Profile
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.
Further Reading
- Five stocks we like better than MiNK Therapeutics
- How to Calculate Inflation Rate
- 3 Defense Stocks Set to Benefit From Increased Military Spending
- What does consumer price index measure?
- Aluminum Tariff Woes: Between 2 Stocks, 1 Shines Brighter
- What Are Some of the Best Large-Cap Stocks to Buy?
- Semtech Rallies on Earnings Beat—Is There More Upside?
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
